ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Yisheng Biopharma Logo

Yisheng Biopharma

We are developing PIKA-based vaccines to prevent or treat infectious disease, including COVID 19, hepatitis B, rabies and flu. YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. YS Biopharma operates in China, Singapore, the United States, the United Arab Emirates and the Philippines with over 800 employees and led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry. When delivered with relevant protein-based molecules, PIKA technology is offering a promising platform for the development of a wide variety of novel biotherapeutics as new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics.

Quick overview

Beijing, China

Founded in 2002

501-1000 Employees

Medium-Sized

Additional information

Working industry

Other

Type of company

Manufacturer

Locations

1 Headquarter

Specialised areas

Biopharma, Biotechnology

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

China


Overall risk estimation:

High


ESG country scores

The ESG Data of countries are based on public sources

Environment

E

Grade (A-E)

View details

Social

C

Grade (A-E)

View details

Governance

E

Grade (A-E)

View details

Headquarter of Yisheng Biopharma

Yisheng Biopharma operates in 1 country around the world

City: Beijing

State: Beijing

Country: China

Locations of Yisheng Biopharma

Get an overview of the locations of Yisheng Biopharma

Location

Country

State

City

Headquarter

China

Beijing

Beijing

Frequently asked questions (FAQ) about Yisheng Biopharma

Some frequent questions that have been asked about Yisheng Biopharma

The company headquarter of Yisheng Biopharma is located in Beijing, Beijing, China. It's worth noting, that the company may have more locations

As of the latest available information Yisheng Biopharma has around 501-1000 employees worldwide.

Yisheng Biopharma was founded in 2002

The company Yisheng Biopharma has it's main focus in the industries of Other

Based on the founding year and the amount of employees the company Yisheng Biopharma seems to be a Medium-Sized at the current state. Note that over time that status can change

Competitors of Yisheng Biopharma

Check out some interesting alternative companies to Yisheng Biopharma

Yapan Bio's Logo

Yapan Bio

Makkajipalli, India

11-50 Employees

2019

We provide services to develop and manufacture high-quality Vaccines and Biologics/Bio-therapeutic, to support global biotechnology and biopharma companies, meeting customer satisfaction in compliance with Quality, Regulatory and GMP expectations. Yapan Bio is a Contract Development and Manufacturing Organization (CDMO) serving the needs of the biotechnology industry, globally. Yapan Bio provides robust process development, appropriate scale-up and compliant GMP manufacturing of Vaccines and Biologics/Bio-therapeutics for human clinical studies across the world. Yapan Bio has established state-of-the-art Process Development and GMP facilities for vaccines and biologics, including higher Bio-Safety levels (up to BSL-2+). To provide customized high-quality integrated services to our partners. Yapan Bio was founded by two industry veterans, Atin Tomar and Nirav Desai, with a proven leadership track record in both technical and leadership roles in the biotechnology industry, globally. Yapan Bio’s focus and expertise is in the development and manufacturing of next generation and highly complex molecules/products (recombinant vaccines, viral and non-viral vector-based products, Gene Therapy, monoclonal antibodies etc.). Optimization and scale-up for high product titer, stability and consistent manufacturing output.

VEROVACCiNES GmbH's Logo

VEROVACCiNES GmbH

Halle (Saale), Germany

1-10 Employees

2017

After validating the novel technology platform (Proof of Concept in several vaccine programs), we are pursuing development of our product pipeline and scaling up manufacturing. We discover and develop innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate modern recombinant combination vaccines.

BunyaVax's Logo

BunyaVax

Lelystad, Netherlands

1-10 Employees

2017

BunyaVax exploits proprietary technology to develop safe and efficacious vaccines against neglected diseases of animals and humans. BunyaVax has developed proprietary technologies to attenuate bunyaviruses and uses these technologies to develop live attenuated vaccines that optimally combine efficacy with safety. BunyaVax prioritizes viral pathogens that affect animal and human health in developing countries and is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) and leading human and animal health pharma. BunyaVax prioritizes viral diseases caused by bunyaviruses and other insect- and tick-borne viruses, including those listed on the WHO Blueprint list. Apart from vaccines, BunyaVax is using proprietary technologies to develop innovative diagnostics.

United Biomedical,Inc's Logo

United Biomedical,Inc

Town of Smithtown, United States

11-50 Employees

1985

We are a multinational biopharmaceutical organization dedicated to the development of diagnostics and immunotherapeutics for the improvement of global health. Founded in 1985, we are a private, closely held company passionate about delivering science-driven innovation with platform capabilities. Our companies cover novel drug discovery and development, CDMO services, and manufacturing capabilities across vaccines, protein and antibodies, specialty injectables and small molecules. Our product pipeline across these companies include the prevention and treatment of indications in neurology, immunology and infectious diseases for both animal and human health. Delivering specialty injectables/ proteins and world-class CMO services.

Generon (Shanghai) Corporation's Logo

Generon (Shanghai) Corporation

Shanghai, China

51-100 Employees

2004

Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. As one of the top biopharmaceutical companies to develop innovative therapies from China for the world, Evive adopts a holistic approach for drug development, combining exceptional preclinical and clinical research capabilities with our world-class in-house manufacture and regulatory expertise as well as extensive global drug development experience. Become a global commercial-stage biopharmaceutical company dedicated to the development of innovative medicines for patients with unmet medical needs in the areas of oncology, inflammatory or metabolic diseases. Build strong global drug development and commercialization capabilities, including cutting-edge innovative R&D centers, strong clinical development teams, well-recognized regulatory affairs experts, large-molecule manufacturing facilities meeting international GMP standards, and specialized commercial teams. Generate a broad product pipeline with worldwide commercialization of F-627 as a novel treatment for chemotherapy-induced neutropenia, one indication of F-652 submitted for market approval in China, two indications in late-stage clinical development, and multiple product candidates in early clinical or pre-clinical development stages that have been developed with first-in-class or best-in-class potential by in-house R&D teams. Building a Broad Product Pipeline with Worldwide Commercialization.

Saiba Animal Health AG's Logo

Saiba Animal Health AG

Schlieren, Switzerland

1-10 Employees

2013

Saiba Animal Health AG was founded as a spin-off company from the University of Zürich in 2013 by Patrik Paulus, Gabriela Senti, Thomas Kündig and Martin Bachmann. In 2014 Saiba Animal Health received a R&D project grant from the Swiss Commission for Technology and Innovation to advance the HypoCat vaccine project and later that year entered into a Commercialization, manufacture, and distribution agreement with Benchmark Holdings PLC. Saiba Animal Health has developed a novel and innovative vaccine platform that is based on non-infectious virus-like particles in order to treat chronic inflammatory diseases, cancer and allergy in pets. Our team of innovative scientists, veterinarians and businessmen has pioneered and developed expertise and proprietary rights relating to a unique virus-like particle (VLP) vaccine nanotechnology platform. Saiba Animal Health was founded as a spin-off company from the University Zurich in 2013.